Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or...
Reexamination Certificate
2006-06-08
2010-06-22
Canella, Karen A (Department: 1643)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
C435S006120, C435S007230, C435S007240, C436S063000, C436S064000
Reexamination Certificate
active
07741023
ABSTRACT:
Tumor necrosis factor (TNF) is capable of inducing apoptosis by interacting with specific TNF receptors on the surface of cancer cells. Because multiple members of TNF ligand and receptor are present within each superfamily, over 300 different ligand-receptor combinations exist. Activated blood leukocytes produce TNF as part of the immune response to cancer, as well as producing chemokines to attract other leukocytes to the site. A method is disclosed of detecting significant induction of a variety of TNF superfamily subtype and chemokine mRNAs in blood leukocytes when whole blood is exposed to heat-aggregated IgG or anti-T cell receptor antibodies as a model of immune system interactions. Substantial individual-to-individual variation is observed in TNF subtypes and chemokines induced. Since peripheral blood leukocytes are the supply of anti-cancer immune cells, the quantitation of ex vivo inducibility of appropriate TNF ligands and chemokines in blood will be useful in individualized cancer immunotherapy. If the tumor mass is small, such as with early invisible metastatic lesions, appropriate TNF assaults may be sufficient to prevent relapse.
REFERENCES:
patent: 4880548 (1989-11-01), Pall et al.
patent: 4925572 (1990-05-01), Pall
patent: 5210015 (1993-05-01), Gelfand et al.
patent: 5491063 (1996-02-01), Fisher et al.
patent: 5683698 (1997-11-01), Chavali et al.
patent: 6692916 (2004-02-01), Bevilacqua et al.
patent: 7332631 (2008-02-01), Hogarth et al.
patent: 2001/0006789 (2001-07-01), Maino et al.
patent: 2002/0006613 (2002-01-01), Shyjan et al.
patent: 2002/0048566 (2002-04-01), El-Deiry et al.
patent: 2002/0106684 (2002-08-01), Kopreski
patent: 2003/0138781 (2003-07-01), Whitehead
patent: 2003/0148345 (2003-08-01), Kopreski
patent: 2004/0265864 (2004-12-01), Mitsuhashi
patent: 2007/0196835 (2007-08-01), Bankaitis-Davis et al.
patent: 2008/0206761 (2008-08-01), Mitsuhashi
patent: 2008/0261207 (2008-10-01), Mitsuhashi
patent: 1243274 (2002-09-01), None
patent: WO 98/47004 (1998-10-01), None
patent: WO 00/76492 (2000-12-01), None
patent: WO 03/040404 (2003-05-01), None
patent: WO 03/059333 (2003-07-01), None
patent: WO 03/090694 (2003-11-01), None
patent: WO03/099312 (2003-12-01), None
patent: WO 2005/044792 (2005-05-01), None
patent: WO 2005/115115 (2005-12-01), None
patent: WO 2006/110091 (2006-10-01), None
patent: WO 2006/116721 (2006-11-01), None
patent: WO 2008/106451 (2008-09-01), None
Wouters et al (Toxicology and Industrial Health, 2002, vol. 18, pp. 15-27).
Rodriguez-Caballero et al (Laboratory Investigation, 2004, vol. 84, pp. 1387-1398).
Warzocha et al (Journal of Clinical Oncology, 1997, vol. 15, pp. 499-508).
Mehmut et al (Urologia International, 2005, vol. 75, pp. 80-87).
Schimanski, C. C., et al., “Effect of Chemokine Receptors CXCR4 and CCR7 on the Metastatic Behavior of Human Colorectal Cancer,”Clinical Cancer Research, vol. 11, No. 5, Mar. 2005, pp. 1743-1750.
Leung, S. Y., et al., “Expression Profiling Identifies Chemokine (C-C Motif) Ligand 18 as an Independent Prognostic Indicator in Gastric Cancer,”Gastroenterology, vol. 127, No. 2, Aug. 2004, pp. 457-469.
Moran, C. J., et al., “RANTES Expression Is a Predictor of Survival in Stage I Lung Adenocarcinoma,”Clinical Cancer Research, vol. 8, No. 12, Dec. 2002, pp. 3803-3812.
Younes, A., et al., “Clinical Implications of the Tumor Necrosis Factor Family in Benign and Malignant Hematologic Disorders,”Cancer, vol. 98, No. 3, Aug. 2003, pp. 458-467.
Younes, A., et al., “Emerging Applications of the Tumor Necrosis Factor Family of Ligands and Receptors in Cancer Therapy,”J. Clin. Oncol., vol. 21, No. 18, Sep. 2003, pp. 3526-3534.
Aggarwal, B. B., et al., “The Role of TNF and Its Family Members in Inflammation and Cancer: Lessons from Gene Deletion,”Curr. Drug Targets Inflamm. Allergy, vol. 1, No. 4, Dec. 2002, pp. 327-341.
Sträter, J., et al., “Expression of Trail and Trail Receptors in Colon Carcinoma: Trail-R1 Is an Independent Prognostic Parameter,”Clinical Cancer Research, vol. 8, No. 12, Dec. 2002, pp. 3734-3740.
Spierings, D. C. J., et al., “Expression of Trail and Trail Death Receptors in Stage III Non-Small Cell Lung Cancer Tumors,”Clinical Cancer Research, vol. 9, No. 9, Aug. 2003, pp. 3397-3405.
Min, Y. J., et al., “Prognostic Significance of Fas (CD95) and Trail Receptors (DR4/DR5) Expression in Acute Myelogenous Leukemia,”Leukemia Research, vol. 28, No. 4, Apr. 2004, pp. 359-365.
Ames et al., “Are vitamin and mineral deficiencies a major cancer risk?” Nature, 2002, 2: 694-704.
Bush et al., Cancer Chemoresistance: The relationship Between P53 and Multidrug Transporters, Int J Cancer, 2002, vol. 98, pp. 323-330.
Chaudhary et al., Prediction of response to infliximab in Crohn's disease, Digestive and Liver Disease, 2005, vol. 37, Issue 8, pp. 559-563.
Christoph Hartel et al., Delayed Cytokine mRNA Expression Kinetics after T-Lymphocyte Costimulation: A Quantitative Measure of the Efficacy of Cyclosporin A-based Immunosuppression, Clinical Chemistry, 2002, vol. 48, Issue 12, pp. 2225-2231.
Darryl See et al., Increased Tumor Necrosis Factor Alpha (TNF-α) and Natural Killer Cell (NK) Function Using an Integrative Approach in Late Stage Cancers, Immunological Investigations, 2002, vol. 31, Issue 2, pp. 137-153.
European Patent Office, EP Search Report for EP 06772657.0, Dec. 2, 2008.
Fischer et al., Melatonin reduces UV-induced reactive oxygen species in a dose-dependent manner in IL-3-stimulated leukocytes, Journal of Pineal Research, 2001, vol. 31, Issue 1, pp. 39-45.
Fukumi Sachiko et al., Differential responses of Bcl-2 family genes to etoposide in chronic myeloid leukemia K562 cells, Molecular and Cellular Biochemistry, Mar. 2000, vol. 206, Issue 1-2, pp. 43-50.
Ghosh et al., Anti-TNF therapy in Crohn's disease, Novartis Foundation Symposium, 2004, vol. 263, pp. 193-218.
Hiroko Matsunaga et al., Application of Differential Display to Identify Genes for Lung Cancer Detection in Peripheral Blood, Int. J. Cancer, 2002, vol. 100, pp. 592-599.
Hoque, et al., PUMA in Head and Neck Cancer, Cancer Letters, 2003, vol. 199 , pp. 75-81.
International Search Report, International Application No. PCT/US08/83136, Jul. 17, 2009.
International Search Report, International Application No. PCT/US07/08559, Sep. 4, 2008.
International Searching Authority, International Search Report for PCT/US2005/037925, Patent Cooperation Treaty, Feb. 21, 2007.
Jamila K. Adam et al., Immune responses in cancer, Pharmacology & Therapeutics, 2003, vol. 99, pp. 113-132.
Juhasz et al., Quantification of Chemotherapeutic Target Gene mRNA Expression in Human Breast Cancer Biopsies: Comparison of Real-Time Reverse Transcription-PCR vs. Relative Quantification Reverse Transcription-PCR Utilizing DNA Sequencer Analysis of PCR Product, Journal of Clinical Laboratory Analysis, 2003, vol. 17, pp. 184-194.
Klein N. J et al., Ex-Vivo Assessment of Candidate Anti-Inflammatory Agents in the Treatment of Gram Negative Sepsis, Immunology and Infectious Diseases, 1994, vol. 4, Issue 1, pp. 33-35.
Liu Feng-Ting et al., Bax conformational change is a crucial step for PUMA-mediated apoptosis in human leukemia, Biochemical and Biophysical Research Communications, Oct. 24, 2003, vol. 310, Issue 3, pp. 956-962.
Mascheretti et al., Pharmacogenetic investigation of the TNF/TNF-receptor system in patients with chronic active Crohn's disease treated with infliximab, The Pharmacogenomics Journal, 2002, vol. 2, Issue 2, pp. 127-136.
Michael R. Verneris et al., Resistance of ex vivo expanded CD3+CD56+ T cells to Fas-mediated apoptosis, Cancer Immunol Immunother, 2000, vol. 49, pp. 335-345.
N. Gopalakrishna Iyer et al., p300 regulates p53-dependent apoptosis after DNA damage in colorectal cancer cells by modulation of PUMA/p21 levels, PNAS, May 11, 2004, vol. 101, Issue 19, pp. 7386-7391.
Plevy et al., A Role for TNF-α and Mucosal T Helper-1 Cytokines in the Pathogenesis of Crohn's Disease, The Journal of Im
Canella Karen A
Hitachi Chemical Co. Ltd.
Hitachi Chemical Research Center Inc.
Knobbe Martens Olson & Bear LLC
LandOfFree
Method for predicting immune response to neoplastic disease... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for predicting immune response to neoplastic disease..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for predicting immune response to neoplastic disease... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4212910